

PharmaMar licenses Analogs of Kahalalide F to Marinomed for Uses outside of Oncology/Neurology

- ***Kahalalide F is a novel depsipeptide developed by PharmaMar from the Hawaiian sea slug *Elysia rufescens*.***
- ***PharmaMar and Marinomed enter into a global collaboration and license agreement on analogs of Kahalalide F for uses outside of Oncology and Neurology.***
- ***PharmaMar shall receive royalties on sales of products from Kahalalide F analogs as well as part of any income that Marinomed may receive from sublicensees.***

Madrid, March 2nd, 2009. PharmaMar SA (Grupo Zeltia, ZEL.MC) and Marinomed Biotechnologie GmbH today announced a License Agreement covering analogs of Kahalalide F for uses outside of Oncology and Neurology.

Kahalalide F is a novel depsipeptide resulting from PharmaMar's internal research program. It is derived from the Hawaiian sea slug *Elysia rufescens*. In preclinical assays performed by Marinomed, certain synthetic analogs of Kahalalide F have shown a favorable activity profile.

With this agreement, Marinomed receives a global license to analogs of Kahalalide F for uses outside of Oncology and Neurology, with the right to sublicense. PharmaMar will collaborate with Marinomed in identifying and synthesizing the most suitable drug candidates and will retain all rights to Kahalalide F analogs for the treatment of cancer and central nervous systems disorders together with all rights on Kahalalide F and two of its related analogs.

All subsequent preclinical and clinical development as well as commercialization will be done by Marinomed and/or its sublicensee(s). PharmaMar shall receive royalties on sales of products based on Kahalalide F analogs as well as part of any income that Marinomed may receive from its sublicensees (upfront payments, milestones, royalties).

"We are excited to enter into a collaboration with a young and dynamic company that shares our vision of developing innovative medicines based on the richness of marine biodiversity," said Luis Mora, General Manager of PharmaMar. "The family of Kahalalide compounds is a source of highly active drug candidates for a range of therapeutic areas, as demonstrated by Irvallec[®] (elisidepsin, PM02734), which recently entered a PharmaMar-sponsored phase II trial in non-small cell lung cancer, and by Kahalalide F, which has shown favorable activity in an exploratory phase II trial in patients suffering severe psoriasis. As we share a similar research model but are focused on different therapeutic areas, Marinomed is the ideal partner for us to exploit the potential of Kahalalide F analogs in important therapeutic areas outside of Oncology and Neurology. In addition, Marinomed impressed

us by having brought to market an innovative marine-derived product (COLDAMARIS PROPHYLACTIC®) in record time”.

Dr. Eva Prieschl-Grassauer, (CSO) of Marinomed, said "We are looking forward to this collaboration with PharmaMar which is a well-known and successful company in this field of blue biotechnology. We are delighted about the opportunity to bring in our know-how and expertise in the fields of immunology and infectious diseases. For Marinomed as a young and innovative company this agreement supports our dynamic company development and together we will be able to develop new innovative drugs which have a high degree of unmet medical need”.

About Kahalalide F

Kahalalide F is a depsipeptide resulting from PharmaMar’s internal research program and is derived from the Hawaiian sea slug *Elysia rufescens*. Kahalalide F itself is not part of the License Agreement between PharmaMar and Marinomed regarding Kahalalide F analogs. PharmaMar is currently working on out-licensing Kahalalide F and two related analogs for the use in dermatological disorders, based on the favorable results obtained in a phase II trial in patients suffering severe psoriasis.

PharmaMar

PharmaMar is the world leader biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines. PharmaMar is marketing one novel compound and has three more in clinical development: Yondelis® received marketing authorisation from the European Commission for the treatment of advanced or metastatic soft tissue sarcoma in September 2007. In 2008 a registration dossier was submitted to the European Medicines Agency (EMA) and Food and Drug Administration (FDA, USA) for Yondelis® when administered in combination with DOXIL®/Caelyx™ (pegylated liposomal doxorubicin) for the treatment of women with relapsed ovarian cancer. It is also in phase II clinical trials for prostate, breast and lung cancers. Three compounds, Aplidin®, Irvalec® and Zalypsis® are in various stages of clinical development. Two further compounds have reached late-stage preclinical trials.

Marinomed

The Marinomed Biotechnologie GmbH was founded in 2006 and is a spin-off company of the Veterinary University Vienna. Marinomed develops innovative drugs from natural-, mainly marine resources in the fields of immunology, allergy and infectious diseases.

The expertise of the team covers the fields of virology/infectious diseases, allergy/immunology and marine biotechnology. This is combined with a strong background in product development in biopharmaceutical and pharmaceutical companies. After less than two years Marinomed presented its first product: an anti-viral nasal spray with a new effective and novel treatment against common cold. For that innovative product Marinomed has won the Vienna Mercur Price for Innovation in 2008.

Important note

PharmaMar, based in Madrid, Spain, is a subsidiary of Grupo Zeltia (Spanish Stock Exchange, ZEL) that is quoted in the Spanish Stock Exchange since 1963. Grupo Zeltia is currently part of the Ibex Nuevo Mercado (New Market). This document is a press release, not a brochure. This document does not constitute nor is part of any offer or invitation to sell or issue any application of purchase, offer or shares subscription of the Society. Likewise, this document nor its distribution is part or can be of base for any contract or investment decision and does not constitute any kind of recommendation in relation with the shares of the Company.

For further information:

Media: Fernando Mugarza, Communication Director, PharmaMar (Tel: 34 91 846 60 56)

Investors: Alfonso Hurtado de Mendoza, Capital Markets (Tel: 34 91 444 45 00)

This press release is also available in the News section of www.pharmamar.com